Home » Press Releases
Acetylon Pharmaceuticals’ Selective HDAC Inhibitors In Multiple Myeloma, Lymphoma And Sickle Cell Disease And β-Thalassemia To Be Featured In 11 Presentations At The American Society Of Hematology Annual Meeting
Published: Nov 25, 2013 9:00 am
Boston (Press Release) - Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, today announced that its selective HDAC inhibitor drug candidates will be the subject of eleven presentations, including three oral presentations and eight poster presentations of preclinical and clinical research in multiple myeloma, lymphoma and sickle cell disease/β-thalassemia at the American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2013, in New Orleans, LA. The presentations will include interim updates of two clinical trials of ACY-1215, a selective HDAC6 inhibitor: a Phase 1/2 trial in combination with bortezomib and dexamethasone and a Phase 1b trial in combination with lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma. In addition, Acetylon and scientific collaborators will present results of preclinical studies of ACY-1215, demonstrating potent combination treatment in disease models of multiple myeloma and lymphoma, along with preclinical studies of its selective HDAC1/2 inhibitors in sickle cell disease and β-thalassemia.
Details of the presentations are as follows:
Multiple Myeloma |
|
Oral Presentation
|
Date: Monday, December 9, 2013 |
Time: 6:15-7:45pm CT |
Location: 393-394 |
Session: 653. Myeloma: Therapy, excluding Transplantation: Advances in Multiple Myeloma and Plasma Cell Leukemia |
Abstract #: 759 |
Title: ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor: Interim Results of Combination Therapy with Bortezomib in Patients with Multiple Myeloma (MM) |
|
Poster Presentations
|
Date: Saturday, December 7, 2013 |
Time: 5:30-7:30pm CT |
Location: Hall G |
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster I |
Abstract #: 1952 |
Title: ACY-1215, a First-In-Class Selective Inhibitor of HDAC6, Demonstrates Significant Synergy with Immunomodulatory Drugs (IMiDs) in Preclinical Models of Multiple Myeloma |
|
Date: Saturday, December 7, 2013 |
Time: 5:30-7:30pm CT |
Location: Hall G |
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I |
Abstract #: 1909 |
Title: Discovery Histone Deacetylase (HDAC)6 Specific Proteomic Biomarkers in Multiple Myeloma (MM) Using Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) |
|
Date: Sunday, December 8, 2013 |
Time: 6:30-8:30pm CT |
Location: Hall G |
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II |
Abstract #: 3190 |
Title: ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, in Combination with Lenalidomide and Dexamethasone (dex), is Well Tolerated Without Dose Limiting Toxicity (DLT) in Patients with Multiple Myeloma at Doses Demonstrating Biologic Activity: Interim Results of a Phase 1b Trial |
|
Date: Sunday, December 8, 2013 |
Time: 6:30-8:30pm CT |
Location: Hall G |
Session: 653. Myeloma: Therapy, excluding Transplantation: Poster II |
Abstract #: 3219 |
Title: Tubulin Hyper-Acetylation in Blood Lymphocytes: Pharmacodynamic (PD) Biomarker for the Selective Histone Deacetylase (HDAC) 6 Inhibitor ACY-1215 in Multiple Myeloma Patients |
|
Date: Monday, December 9, 2013 |
Time: 6:00-8:00pm CT |
Location: Hall G |
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III |
Abstract #: 4437 |
Title: Preclinical Combination of the Oral Investigational Agents ACY-1215, a Selective HDAC6 Inhibitor, and Ixazomib, a Proteasome Inhibitor, Demonstrates Combination Benefit in Multiple Myeloma Cell Lines and Xenograft Models |
|
Date: Monday, December 9, 2013 |
Time: 6:00-8:00pm CT |
Location: Hall G |
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster III |
Abstract #: 4431 |
Title: Inhibition of Autophagy by ACY-1215, a Selective HDAC6 Inhibitor, Accelerates Carfilzomib-Induced Cell Death in Multiple Myeloma |
|
Lymphoma |
|
Oral Presentation
|
Date: Monday, December 9, 2013 |
Time: 4:30-6:30pm CT |
Location: 220-222 |
Session: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Small Molecule Targets in Lymphoma |
Abstract #: 648 |
Title: Dual Targeting with the Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads to Marked Disruption of Protein Degradation Pathways and Apoptosis in Preclinical Models of Lymphoma |
|
Poster Presentation
|
Date: Sunday, December 8, 2013 |
Time: 6:30-8:30pm CT |
Location: Hall G |
Session: 625. Lymphoma: Preclinical – Chemotherapy and Biologic Agents: Poster II |
Abstract #: 3071 |
Title: Inhibition of HDAC6 in Combination with Targeted Agents Results in Broad Synergistic Decreases in Viability in Non-Hodgkin’s Lymphoma (NHL) Cells |
|
Sickle Cell Disease/β-Thalassemia |
|
Oral Presentation
|
Date: Monday, December 9, 2013 |
Time: 4:30-6:00pm CT |
Location: 343-345 |
Session: 112. Thalassemia and Globin Gene Regulation: Preclinical and Clinical Therapeutic Strategies for Thalassemia |
Abstract #: 564 |
Title: Pharmacological Inhibition of Histone Deacetylase (HDAC) 1, 2 or 3 have Distinct Effects on Cellular Viability, Erythroid Differentiation, and Fetal Globin (HbG) Induction |
|
Poster Presentation
|
Date: Sunday, December 8, 2013 |
Time: 6:30-8:30pm CT |
Location: Hall E |
Session: 112. Thalassemia and Globin Gene Regulation: Poster II |
Abstract #: 2253 |
Title: Mechanistic Insights into Fetal Hemoglobin (HbF) Induction Through Chemical Inhibition of Histone Deacetylase 1 and 2 (HDAC1/2) |
|
About Acetylon
Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company’s epigenetic drug discovery platform has yielded a proprietary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon’s lead drug candidate, ACY-1215, is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma. The Company recently announced a strategic collaboration agreement with Celgene Corporation, which includes an exclusive option for the future acquisition of Acetylon by Celgene. Acetylon’s scientific founders are affiliated with the Harvard University, the Dana-Farber Cancer Institute, the Massachusetts General Hospital, the Broad Institute and Harvard Medical School. www.acetylon.com
Source: Acetylon Pharmaceuticals.